2021
DOI: 10.1186/s12906-021-03246-w
|View full text |Cite|
|
Sign up to set email alerts
|

Thymoquinone inhibited vasculogenic capacity and promoted mesenchymal-epithelial transition of human breast cancer stem cells

Abstract: Background Vasculogenic mimicry (VM) is characterized by the formation of tubular structure inside the tumor stroma. It has been shown that a small fraction of cancer cells, namely cancer stem cells (CSCs), could stimulate the development of vascular units in the tumor niche, leading to enhanced metastasis to the remote sites. This study aimed to study the inhibitory effect of phytocompound, Thymoquinone (TQ), on human breast MDA-MB-231 cell line via monitoring Wnt/PI3K signaling pathway. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
16
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 17 publications
(16 citation statements)
references
References 47 publications
0
16
0
Order By: Relevance
“…In vitro studies on MDA-MB-231 cancer stem cells, TQ inhibited Wnt3a and PI3K and blunted the stimulatory effects of VEGF, EGF, and FGF. The study was further confirmed by demonstrating a lack of cellular response to pro-angiogenesis factors [ 158 ]. These data suggest that targeting CAFs are being considered to control TNBC using TQ.…”
Section: Thymoquinone (Tq) Targeting the Cellular Components Of Tmementioning
confidence: 87%
See 1 more Smart Citation
“…In vitro studies on MDA-MB-231 cancer stem cells, TQ inhibited Wnt3a and PI3K and blunted the stimulatory effects of VEGF, EGF, and FGF. The study was further confirmed by demonstrating a lack of cellular response to pro-angiogenesis factors [ 158 ]. These data suggest that targeting CAFs are being considered to control TNBC using TQ.…”
Section: Thymoquinone (Tq) Targeting the Cellular Components Of Tmementioning
confidence: 87%
“…Preventing or blocking the tumor blood supply by disrupting the new blood cell formation has been considered as a general strategy to treat cancer [ 251 ]. TQ could be used to target TGF-B, VEGF, and other angiogenic factors in TNBC [ 158 , 209 , 252 ]. Targeting endoglin and its downstream pathways as an approach for treating TNBC with TQ would be another potential target site in this regard ( Figure 6 ).…”
Section: Thymoquinone (Tq) Targeting the Cellular Components Of Tmementioning
confidence: 99%
“…Similarly, TQ induced cell cycle arrest and apoptosis of MCF7 and MDA-MB-231 through downregulation of PI3K/AKT signaling. 44 , 45 …”
Section: Discussionmentioning
confidence: 99%
“…Moreover, CD44+CD24− bCSCs when incubated with TQ can interfere with rhodamine-123 efflux and decrease stemness. This observation indirectly denotes that thymoquinone relieves the drug-resistance properties of bCSCs ( 84 ). Mechanistically, TQ suppresses the PI3K and Wnt3a signaling, leading to the reduction of the p-Akt/Akt ratio, and has the potential to reduce the number of bCSCs.…”
Section: Bcscs and Drug Resistancementioning
confidence: 99%